临床试验/NCT00158379

NCT00158379已完成2 期

Carboplatin With Following Taxol® Therapy Under Additional Application of Epoetin Alfa (ERYPO ®) With Female Patients With Advanced Ovarian Cancer FIGO IA/G3 - IV

North Eastern German Society of Gynaecological Oncology0 个研究点目标入组 105 人开始时间: 2003年7月最近更新: 2017年2月6日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: North Eastern German Society of Gynaecological Oncology
入组人数: 105
主要终点: Progression-free Survival. Progression is Defined According WHO-criteria as Appearance of Any New Lesion or Increase of Existing Lesions by at Least 25%

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Time to progression (physical examination and radiologic imaging

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•patients with primary ovarian cancer
•ECOG- 0-2
•Age >= 18
•no chemotherapy, radiation or immunotherapy in medical history for ovarian cancer
•adequate bone marrow, liver and kidney reserve: leukocytes ≥ 2.0 x 109/l, platelets ≥ 100 x 109/l, bilirubin <= 2,0 mg%, creatinine <= 1,5 mg% or creatinine clearance ≥ 60 ml/ min, hemoglobin ≥ 9 g/ dl SGOT, SGPT an AP within 3 fold of the reference laboratory's normal range
•written informed consent

排除标准

•before-existing heart illness, Cardiac infarct within last 6 months
•Radiotherapy within 4 weeks for study entry
•Patients in pregnancy or breast feeding (in premenopausal women anticonception has to be assured: intrauterine devices, surgical methods of sterilization, or, in hormone insensitive tumors only, oral, subcutaneous or transvaginal hormonal, non-estrogen containing contraceptives)

研究组 & 干预措施

Paclitaxel

Experimental

干预措施: Paclitaxel (Drug)

结局指标

主要结局

Progression-free Survival. Progression is Defined According WHO-criteria as Appearance of Any New Lesion or Increase of Existing Lesions by at Least 25%

时间窗: every 3 months for up to 3 years

Time to progression

次要结局

Toxicity(after every cycle during therapy phase and after every 3 months during follow-up, for up to 3 years)

研究者

发起方

North Eastern German Society of Gynaecological Oncology

申办方类型

Other

责任方

Sponsor

相似试验

已完成

2 期

Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian CancerOvarian Cancer

NCT00170664North Eastern German Society of Gynaecological Oncology129

已完成

2 期

Phase II study of Carboplatin, weekly Paclitaxel and Bevacizumab in elderly patients with advanced non-squamous non-small-cell lung cancer (NEJ 016)non-small cell lung cancer

JPRN-UMIN000006622orth East Japan Study Group36

已完成

2 期

A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancerThymic cancer

JPRN-UMIN000001358West Japan Oncology Group40

招募中

不适用

Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumoniaadvanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia

JPRN-UMIN000018322IP lung cancer study group35

已完成

2 期

A Phase II Study of Carboplatin+weekly Paclitaxel+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous, non-small cell lung cancer.

JPRN-UMIN000003674Kochi University, School of Medicine, Department of Hematology and Respiratory Medicine43